

RECEIVED
CENTRAL FAX CENTER

MAR 19 2004

OFFICIAL

Re: U.S. Patent Application No. 10/620,619 filed 07/17/2003
Title: 5-Aryltetrazole Compounds, Compositions Thereof, and Uses Therefor
First Inventor: Alex Nivorozhkin
Examiner: To Be Assigned Group Art Unit: 1616
Attorney Docket No.: 289591.136 US1

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office to:

TC 1600 Before Final (703) 872-9306

on 3/19/2004
Date

Erica M Brauer

Signature

Erica M. Brauer

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Document	No. Pgs.
Information Disclosure Statement	1
PTO 1449 List of References	5

Total Number of Pages (including this Certificate of Transmission)

7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nivorozhkiu et al. Examiner: To Be Assigned
U.S. Serial No.: 10/620,619 Art Unit: 1616
Filing Date: July 17, 2003
For: 5-Aryltetrazole Compounds, Compositions Thereof, and Uses Therefor
Docket No.: 289591.136 US1 (formerly 11078-029-999)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the references AA through DN listed on the attached PTO-1449 Form.

References AA through DN were previously submitted to or cited by the Patent Office in connection with parent application U.S. Serial No. 10/197,609, filed July 18, 2002, which applicants rely on for an earlier effective filing date under 35 U.S.C. § 120. Accordingly, applicants have not provided a copy of the references herewith. Should the Examiner desire a copy of any of the references AA through DN, applicants would be glad to provide a copy.

It is respectfully requested that the Examiner make references AA through DN of record by initialing and returning a copy of the enclosed PTO Form 1449 with the next Patent Office communication.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement. However, the Commissioner is authorized to debit any necessary fee or credit any overpayment relating to the above-identified application to Deposit Account No. 08-0219.

Date: March 19, 2004

Respectfully submitted,

Matthew E. Langer, Reg. No. 36,343

Matthew E. Langer
Registration No. 36,343
Attorney for Applicants

Hale and Dorr LLP
300 Park Avenue
New York, New York 10022
(212) 937-7227-Phone
(212) 937-7300-Facsimile

NEWYORK 88664v1

Subt. For. PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616	
Sheet	1	OF	5				

U.S. Patent Documents							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,277,998	8/21/2001	Ushio			
	AB	6,191,289	2/20/2001	Ushio			
	AC	5,874,593	2/23/1999	Ushio			
	AD	5,284,954	2/8/1994	Wittenberger			
	AE	6,388,088	5/14/2002	Sidduri			
	AF	5,049,572	9/17/1991	Scherrer et al.			
	AG	5,232,937	8/3/1993	Makovec et al.			
	AH	5,364,889	11/15/1994	De et al.			
	AI	5,663,357	9/2/1997	Teng et al.			
	AJ	5,976,576	11/2/1999	Makovec et al.			
	AK	6,297,261	10/2/2001	Christopherson et al.			
	AL	6,417,393	7/9/2002	Christopherson et al.			
	AM	2002/0032210	8/1/2002	Pinto et al.			
	AN	2002/0032210	3/14/2002	Dahl et al.			
	AO	2002/0037905	3/28/2002	Dahl et al.			
	AP	6,696,479	2/24/2004	Van Der Schaaf et al.			
	AQ	6,706,749	3/16/2004	Dahl et al.			
Foreign Patent Documents							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AR	WO 02/00647	1/03/2002	PCT			
	AS	WO 01/85705	11/15/2001	PCT			
	AT	0638553	7/26/1994	Europe			
	AU	WO 90/09989	9/7/1990	PCT			
	AV	WO 93/16053	8/19/1993	PCT			
	AW	WO 98/58522	12/23/1998	PCT			
	AX	WO 99/24442	5/20/1999	PCT			
	AY	WO 00/16798	3/30/2000	PCT			
	AZ	WO 00/24707	5/4/2000	PCT			
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.							

NEWYORK 90029v1

Subl. For, PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616	
Sheet	2	OF	5				

	BA	WO 00/28879	5/25/2000	PCT				
	BB	WO 00/64888	11/2/2000	PCT				
	BC	WO 01/66098	9/13/2001	PCT				
	BD	WO 02/00847	1/3/2002	PCT				

Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)								
	BE	Oda et al., Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD, Science. 1989 May 26;244(4907):974-6.						
	BF	Tan et al., Xanthine oxidase activity in the circulation of rats following hemorrhagic shock, Free Radic Biol Med. 1993 Oct;15(4):407-14.						
	BG	McCord J.M., Oxygen-derived free radicals in postischemic tissue injury, N Engl J Med. 1985 Jan 17;312(3):159-63.						
	BH	Miesel et al., "Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood", Inflammation. 1994 Dec;18(6):597-612.						
	BI	Engerson et al., Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues, J Clin Invest. 1987 Jun;79(6):1564-70.						
	BJ	Akaide et al., Dependence on O ₂ - generation by xanthine oxidase of pathogenesis of influenza virus infection in mice, J Clin Invest. 1990 Mar;85(3):739-45.						
	BK	Katal et al., Am Rev. Resp. Dis. 136:98-101						
	BL	Mohacs et al., Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in response to various stimuli, Biochim Biophys Acta. 1996 Aug 23;1316(3):210-6.						
	BM	Friedl et al., Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. 1990 Mar;136(3):491-5.						
	BN	Friedl et al., Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am J Pathol. 1989 Jul;135(1):203-17.						
	BO	Parks et al., Role of oxygen free radicals in shock, ischemia, and organ preservation. Surgery. 1993 Sep;94(3):428-32.						
	BP	Demling et al., Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes. Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1272-8.						
	BQ	Chambers et al., Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol. 1985 Feb;17(2):145-52.						
	BR	Deltch et al., Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation. Surgery. 1988 Aug;104(2):191-8.						
	BS	Mayumi et al., Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock. 1996 May;5(5):324-32.						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

NEWYORK 90029v1

Subt. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Number 289591.136 US1		Application Number 10/620,619	
				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616	
Sheet	3	OF	5				

BT	Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock. J Trauma. 1994 Dec;37(6):956-61.
BU	Zollei, I., Experimental study of hypovolaemic shock-induced gastric mucosal lesions in the rat. Ann Acad Med Singapore. 1999 Jan;28(1):85-9.
BV	Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock. J Trauma. 1994 Dec;37(6):956-61.
BW	Modelski et al., Inhibition of beta-adrenergic-dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock. Am J Physiol. 1999 May;276(5 Pt 1):L844-57.
BX	Flynn et al., Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function. J Surg Res. 1997 Mar;68(2):175-80.
BY	Mannion et al., Role of xanthine oxidase inhibition in survival from hemorrhagic shock. Circ Shock. 1994 Jan;42(1):39-43.
BZ	Cunningham and Keaveny, Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock. Eur Surg Res. 1978;10(5):305-13.
CA	Youn et al., Oxidants and the pathophysiology of burn and smoke inhalation injury. Free Radic Biol Med. 1992;12(5):409-15.
CB	Deitch et al., A study of the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation. J Trauma. 1992 Feb;32(2):141-7.
CC	Anderson et al., Hypovolemic shock promotes neutrophil sequestration in lungs by a xanthine oxidase-related mechanism. J Appl Physiol. 1991 Nov;71(5):1862-5.
CD	Poggetti et al., Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma. 1992 Jun;32(6):723-7; discussion 727-8.
CE	Nielsen et al., Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg. 1995 Sep;110(3):715-22.
CF	Schwartz et al., Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol. 1995 Apr;12(4):434-40.
CG	Crowell et al., Effect of allopurinol on hemorrhagic shock. Am J Physiol. 1969 Apr;216(4):744-8.
CH	Linder et al., Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. 1999 Aug;79(8):967-74.
CI	Saksela et al., Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol Neonate. 1998 Oct;74(4):274-80.
CJ	Battelli et al., Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). Clin Chim Acta. 1999 Mar;281(1-2):147-59.
CK	Houston et al., Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signalling. J Biol Chem. 1999 Feb 19;274(8):4985-94.
CL	Fox et al., Immunohistochemical localization of xanthine oxidase in human retina. Free Radic Biol Med. 1998 Apr;24(6):900-5.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

NEWYORK 90029-1

Subt. For, PTO-1449				Docket Number 289591.136 US1	Application Number 10/620,619
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.	
				Filing Date July 17, 2003	Group Art Unit 1616
Sheet	4	OF	5		

CM	Rouquette et al., Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett. 1998 Apr 24;426(3):397-401.
CN	Cardillo et al., Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997 Jul;30(1 Pt 1):57-63.
CO	Page et al., Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. 1998 Jul 23;1381(2):191-202.
CP	Zhang et al., Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun. 1998 Aug 28;249(3):767-72.
CQ	Trujillo et al., Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem. 1998 Apr 3;273(14):7828-34.
CR	Goldfinger, S.E., Treatment of gout. N Engl J Med. 1971 Dec 2;285(23):1303-6.
CS	Buchanan et al., Hypocholesterolemic 5-substituted tetrazoles. J Med Chem. 1969 Nov;12(6):1001-6.
CT	Shukla and Rastogi, Studies on neuropharmacological and biochemical properties of 5-substituted tetrazoles. Indian J Physiol Pharmacol. 1981 Oct-Dec;25(4):369-73.
CU	Springer et al., 1916, J. Med. Chem. 19, 291: U.S. Patent No.: 4,021,556
CV	Skipper et al., Inhibition of experimental neoplasms by 4-aminopyrazolo (3, 4-d) pyrimidine. Proc Soc Exp Biol Med. 1955 Aug;89(4):594-6.
CW	Demko and Sharpless, Preparation of 5-substituted 1H-tetrazoles from nitriles in water. J Org Chem. 2001 Nov 30;66(24):7945-50.
CX	Butler, R.N., Comprehensive Heterocyclic Chemistry, Katritzky, et al., Eds., Pergamon: Oxford, U.K., 1996, Volume 4.
CY	Isida et al., The Formation of Tin-Nitrogen Bonds. V. The Selective 1-Substitution Reaction of 5-Substituted 1-(Tri-n-butylstannyl) tetrazoles with Methyl Iodide, Methyl p-Toluenesulfonate, Dimethyl Sulfate, and Ethyl Bromoacetate. Chemical Society of Japan, Vol. 46, 2176-2180.(1973)
CZ	Rosenbaum et al., 1992, "Thermolyse von 1-Thiocarbamoyl-5-phenyl-tetrazolen", J. Prakt. Chem. 384:283-4.
DA	Yu E. Myznikov et al., Tetrazoles XXV. Production of N-Benzoyltetrazoles and their Chemical Characteristics
DB	A. Konnecke et al., 1976, Tetrahedron letters, No. 7, 533-538.
DC	Oslpova et al., Tetrazoles. XIX Acylation of Tetrazoles under the Conditions of Phase-Transfer Catalysis
DD	Jursic B.S., 1993, "Acyltetrazole As an Intermediate for Preparation of Carboxylic Acid Derivatives", Synthetic Communications, 23(3):361-4.
DE	Ishibuchi et al., Synthesis and Structure-Activity Relationships of 1-Phenylpyrazoles as Xanthine Oxidase Inhibitors" Biorganic and Medicinal Chemistry Letters, V. 7, 4 pgs.
DF	Nagamatsu et al., "Novel xanthine oxidase inhibitor studies. Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-substituted 6-alkyl-idenehydrazino- or 6-aryl-methylidenehydrazino-7H purines and 3- and/or 5-substituted 9H-1,2,4-triazolo [3,4-l] purines", Faculty of Pharmaceutical Sciences, Okayama University, Tsushima, Okayama, 700-8530, Japan.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

NEWYORK 90029-1

Subt. For, PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616	
Sheet	5	OF	5				

DG	Baldwin et al., 1975, "4-Trifluoromethylimidazoles and 5-(4-Pyridyl)-1,2,4-triazoles, New Classes of Xanthine Oxidase Inhibitors: J. Of Med. Chemistry, v. 18 no. 9.
DH	J. of Org. Chem of the USSR, Russian Original Vol. 20., no. 5, Part 2, May 1984.
DI	Czuczwar et al., A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998 Aug;8(3):233-8.
DJ	Czuczwar et al., Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. J Neural Transm. 1996;103(12):1371-9.
DK	Makovec F., Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. J Med Chem. 1992 Oct 2;35(20):3633-40.
DL	Revel et al., CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992 Dec 8;229(1):45-53.
DM	Revel et al., Pharmacological profile of CR 2039 (Dizolast) a new agent for the treatment of allergic diseases. Life Sciences, 229:273-7. 1992.
DN	Persiani et al., Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm Drug Dispos. 2001 Mar;22(2):73-81.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609; Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

NEWYORK 90029v1